Loading...
Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY
In the past decade, many cardiovascular outcome trials (CVOT) on the efficacy and safety of glucose-lowering agents have been completed. Amongst newer agents available for treatment of type 2 diabetes mellitus (T2DM), sodium-glucose cotransporter-2 (SGLT2) inhibitors have garnered much attention in...
Na minha lista:
| Udgivet i: | Diabetes Obes Metab |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8018526/ https://ncbi.nlm.nih.gov/pubmed/32267076 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13987 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|